Clinical trials: Biliary Cancers
Biliary Tract Cancer
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)
ASCEND-BTC is a prospective, multi-center, observational study aimed at detecting early biliary tract cancer by combined assays of serum protein and cell-free DNA (cfDNA) methylation.
- Trial name
- NCT05667350
- Testing
- Blood drawing
- Where
- 2 sites in China
- Volunteers
- 492 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Biliary Disease, Common Bile Duct Calculi
Needle Knife Fistulotomy Versus Partial Ampullary Endoscopic Mucosal Resection for Difficult Biliary Cannulation
The aims of this study are to compare the needle knife fistulotomy (NKF) technique versus the partial ampullary endoscopic mucosal resection (PA-EMR) technique in patients with difficult biliary cannulation and to assess the…
- Conditions
- Biliary Disease, Common Bile Duct Calculi, Biliary Stricture, Malignant Hepatobiliary Neoplasm
- Trial name
- NCT05068739
- Testing
- PA-EMR, NKF
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Duzce University
Cholangiocarcinoma, Gallbladder Cancer
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- BOLSTER (NCT05712356)
- Testing
- certepetide, Durvalumab, Cisplatin
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- Lisata Therapeutics, Inc.
Biliary Tract Cancer
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
This clinical trial is an open-label, multicenter, phase 3 clinical trial to study the efficacy and safety of adjuvant gemcitabine + capecitabine combination treatment in patients with resectable biliary tract cancer according to…
- Trial name
- NCT04401709
- Testing
- Gemcitabine/Capecitabine, Capecitabine
- Where
- South Korea
- Volunteers
- 490 people
- Sponsor
- Samsung Medical Center
Biliary Tract Neoplasms, Immunotherapy
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Explore the impact of the first-line application of Durvalumab combined with Lenvatinib, with or without chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers.
- Trial name
- NCT05935579
- Testing
- Durvalumab, Lenvatinib Oral Product, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Biliary Tract Cancer
Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing
The purpose of this study is to investigate genetic mutations affecting prognosis using whole genome sequencing in patients with biliary tract cancer.
- Trial name
- NCT03718897
- Testing
- Endoscopic retrograde cholangiopancreatogram
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Ji Kon Ryu
Benign Neoplasm of Liver and/or Biliary Ducts, Neoplasm of Uncertain Behavior of Biliary System
Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts
Single operater pancreatico-cholangioscopy is performed through the working channel of conventional duodenoscopes. A visual evaluation of the biliary and pancreatic ductal systems is completed and obvious or suspicious…
- Conditions
- Benign Neoplasm of Liver and/or Biliary Ducts, Neoplasm of Uncertain Behavior of Biliary System, Benign Neoplasms of the Pancreas, Neoplasms of the Pancreas
- Trial name
- NCT02057146
- Testing
- Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Karolinska University Hospital
Biliary Tract Neoplasms
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
The purpose of this trial is to evaluate the effect of investigational drug nivolumab in combination with either gemcitabine/cisplatin chemotherapy, or in combination with another investigational agent ipilimumab in patients with…
- Trial name
- NCT03101566
- Testing
- Gemcitabine, Cisplatin, Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gastric Cancer, Esophageal Cancer
Perception Prognosis, Goals of Treatment, and Communication
The purpose of this research study is to assess what the participant understands about their illness, prognosis, the goals of the cancer treatment and their communication with their oncology providers.
- Conditions
- Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT01401894
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Biliary Tract Cancer
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy Secondary…
- Trial name
- NCT01234051
- Testing
- Docetaxel, Oxaliplatin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Korean South West Oncology Group
Hepatocellular Carcinoma, Cholangiocellular Carcinoma
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC) patients with platelet counts 100,000/µL.
- Conditions
- Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer
- Trial name
- Gem-ox (NCT00832637)
- Testing
- Cisplatin, Erlotinib, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- New Mexico Cancer Research Alliance
Metastatic Disease
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
An open-label, uncontrolled, multicenter phase I/Ib trial to investigate safety and efficacy of BIBW 2992 added to the standard therapy of Gemcitabine/Cisplatin in chemo-naïve patients with advanced and/or metastatic…
- Trial name
- NCT01679405
- Testing
- BIBW 2992
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Johannes Gutenberg University Mainz
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
The BILLIONSTARS study is a prospective, single arm observational study inviting patients diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery…
- Trial name
- BILLIONSTARS (NCT06877637)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Gallbladder Cancer, Initially Unresectable
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Study design: Prospective, single-arm, single-center phase II clinical study; Primary endpoint: Objective response rate via investigator, Safety; Secondary endpoints: disease control rate, disease-free survival, overall survival…
- Conditions
- Gallbladder Cancer, Initially Unresectable, the First Line Treatment
- Trial name
- NCT05757336
- Testing
- Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Lu Wang, MD, PhD
Cirrhosis, Biliary Atresia
Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis
The aim of this study was to developed and validated models to predict hepatic decompensation and survivals in pediatric patients with cirrhosis and compared these models with currently available models.
- Conditions
- Cirrhosis, Biliary Atresia, Choledochal Cyst, Primary Sclerosing Cholangitis
- Trial name
- NCT05181332
- Testing
- Prediction model
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
Pancreatic Cancer
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to…
- Trial name
- NCT02674100
- Testing
- Registry
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 500 people
- Sponsor
- University of Louisville
Cholangiocarcinoma, Pancreatic Cancer
Registry for Advanced Endoscopy
Observational registry including endoscopic diagnostic and therapeutic interventions in the gastrointestinal tract
- Conditions
- Cholangiocarcinoma, Pancreatic Cancer, Sclerosing Cholangitis
- Trial name
- ERDB (NCT05187312)
- Testing
- Endoscopic retrograde Cholangio- pancreatography, Endoscopic ultrasound
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Region Stockholm
Liver Fibrosis, Liver Cirrhosis
Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity
Liver stiffness measurement (LSM) by non invasive methods is increasingly used to estimate liver fibrosis in patients with chronic liver diseases.
- Conditions
- Liver Fibrosis, Liver Cirrhosis, Viral Hepatitis, Liver Tumour
- Trial name
- NARFI (NCT01082419)
- Testing
- ARFI measurement
- Where
- France
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Metastatic Biliary Tract Cancer, HER2 Positive
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance…
- Trial name
- NCT06818773
- Testing
- Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor
- Volunteers
- 35 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.